New UTI Guideline Offers Treatment Clarity, but Reveals Pressing Gaps in Research
November 20, 2024

The recommendations from WikiGuidelines are the first for UTI prevention, diagnosis, and management in over a decade.

Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents
November 20, 2024

Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.

Treatment for Agitation in Alzheimer Dementia: Pipeline Preview with George Grossberg, MD
November 20, 2024

"It's a very rich pipeline because [agitation] is a very common and very debilitating symptom in Alzheimer's disease," Grossberg observed.

Metabolic Bariatric Surgery Takes a Backseat as GLP-1RA Use Rises: Daily Dose
November 20, 2024

Your daily dose of the clinical news you may have missed.

Exercise of Any Level Linked to Reduced All-Cause Mortality in Individuals with Dementia
November 19, 2024

Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.

ECLIPSE Trial of Cell-Free DNA Blood-Based CRC Screening Test: Expert Overview
November 19, 2024

William Grady, MD, coauthor of the ECLIPSE clinical trial, discusses the study's rationale, methods, and key findings.

The Liver Meeting 2024: Bausch Health Presents Phase 3 Study Design for Investigational Rifaximin Formulation to Delay OHE
November 19, 2024

The RED-C clinical trial program highlights the promising potential of the rifaximin soluble solid dispersion immediate-release tablets for delaying early HE-related decompensation.

2025 GOLD Report for COPD: MeiLan Han, MD, MS, Discusses Addition of Dupilumab, Ensifentrine
November 19, 2024

The 2 newly approved COPD therapies have been added to the GOLD guidelines section on follow-up therapy, expanding clinical options for specific patient types.

Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
November 19, 2024

Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.

Awareness of Lung Cancer Screening Extremely Low Among Those at Highest Risk in the US: New Data
November 18, 2024

Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.